Turn Therapeutics Posts $6.2M Q3 Loss; HS Trial Pulled Forward to Q1 2027
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics reported a $6.2 million Q3 2026 net loss — mostly a non-cash derivative remeasurement — with $10.4 million in cash funding operations into Q3 2027. It also pulled its hidradenitis suppurativa trial start forward to Q1 2027.
Key Events · Earnings and Guidance · TTRX
-
Q3 Loss Widens on Non-Cash Charge
Net loss was $6.2 million, or $(0.21) per share, versus $1.9 million, or $(0.07), a year earlier. The swing is largely a $3.34 million non-cash loss from change in fair value of a derivative liability instrument, not an operating cash outflow.
-
Cash Runway Into Q3 2027
Cash and cash equivalents were $10.4 million at September 30, 2026. Management expects that to fund the Phase 2b atopic dermatitis trial and planned Phase 2a HS trial into Q3 2027, with additional tranches available from existing facilities.
-
HS Trial Start Pulled Forward
Enrollment in the roughly 80-patient Phase 2a hidradenitis suppurativa trial is now expected to begin in Q1 2027, ahead of the previously announced Q2 2027 target.
-
Phase 2b Topline Due Q1 2027
The 120–136 patient Phase 2b atopic dermatitis trial has recorded no dropouts to date; topline results are expected in Q1 2027.
Analysis · TTRX · Life Sciences
The widening loss is the quarter's headline: $6.2 million versus $1.9 million a year ago. Most of that swing reflects a $3.34 million non-cash mark-to-market charge on a derivative liability, not operating spend, which actually fell slightly to $1.98 million. Cash of $10.4 million is enough to fund operations into Q3 2027, and management says additional tranches are available from existing facilities — meaningful given the going-concern doubt previously disclosed in the Q2 10-Q. On the clinical side, the HS Phase 2a trial is now expected to start in Q1 2027, ahead of the prior Q2 target, and Phase 2b atopic dermatitis topline is due Q1 2027, so the next several months carry two readouts/enrollment milestones.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.5M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.